KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for Royalty Pharma (RPRX) over the last 6 years, with Q3 2025 value amounting to $0.67.

  • Royalty Pharma's EPS (Basic) fell 4508.2% to $0.67 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.76, marking a year-over-year decrease of 3151.75%. This contributed to the annual value of $2.97 for FY2024, which is 1690.31% up from last year.
  • Royalty Pharma's EPS (Basic) amounted to $0.67 in Q3 2025, which was down 4508.2% from $0.07 recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's EPS (Basic) peaked at $1.22 during Q3 2024, and registered a low of -$1.04 during Q4 2022.
  • Over the past 5 years, Royalty Pharma's median EPS (Basic) value was $0.32 (recorded in 2022), while the average stood at $0.41.
  • Per our database at Business Quant, Royalty Pharma's EPS (Basic) plummeted by 90375.95% in 2022 and then surged by 540000.0% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's EPS (Basic) stood at $0.13 in 2021, then plummeted by 903.76% to -$1.04 in 2022, then surged by 206.73% to $1.11 in 2023, then tumbled by 32.79% to $0.75 in 2024, then fell by 10.19% to $0.67 in 2025.
  • Its last three reported values are $0.67 in Q3 2025, $0.07 for Q2 2025, and $0.55 during Q1 2025.